NEWS!
- 26/09/2022
The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.
-
06/09/2022
A third collaboration meeting took place today in the French ANR project REPARE, to review the progresses on the development of a high power Bi target for the production of At-211.
- 15/06/2022
1st projects have been selected in PRISMAP-The European medical isotope programme.
- 27/05/2022
Plenary presentation on new developments exploiting isotope mass separation in nuclear medicine presented at the 1st AccConf'22 at IAEA.
-
02/05/2022
MEDICIS restarts its program today. Mass separation will be applied to purify and separate Sm-153 from a target produced at BR2. Some details on the project here.
- 04/02/2022
World cancer day: webinar at 11:30 on MEDICIS mass separation and its impact on theranostics here.
- 29/11/2021
The 1st call for user projects of PRISMAP is launched! More information here.
- 23/09/2021
PRISMAP-The European medical radionuclides programme sets out to substantially change the European landscape for novel and emerging medical radionuclides. More information here.
JOB OPPORTUNITIES
- Opening for a postdoc position at TRIUMF with a focus on mercury-197 radiochemistry and chelation. More details on https://triumf.wd10.myworkdayjobs.com/en-US/careers-at-triumf-job-posti…, post JR100262
A KNOWLEDGE TRANSFER SUCCESS STORY
GRANTS & DONATIONS - CERN & Society Foundation
The CERN KT-Fund
La Fondation pour l'innovation sur le cancer et la biologie
The ADAM company
The FWO
